Zhang Yaowen, Gao Junhui, Zheng Anping, Yang Haijun, Li Jian, Wu Shouxin, Zhao Jiangman, Meng Peng, Zhou Fuyou
Department of Radiation Oncology, Anyang Cancer Hospital, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang 455000, China.
Shanghai Zhangjiang Institute of Medical Innovation, Biotecan Pharmaceuticals co., ltd., Shanghai 201204, China.
Transl Oncol. 2021 Jun;14(6):101066. doi: 10.1016/j.tranon.2021.101066. Epub 2021 Mar 18.
Early recurrence after surgery could affect cancerous patients' prognosis, but the definition of early recurrence and its risk factors for esophageal squamous cell carcinoma (ESCC) patients are still unclear. This study analyzed the clinical data of 468 post-surgery recurrent ESCC patients retrospectively. A minimum p-value approach was used to evaluate the optimal cut-off value of recurrence free survival (RFS) to define early recurrence. Risk factors of early recurrence were developed based on a Cox model. The optimal cut-off value of RFS to distinguish early recurrence was 21 months (p <0.001). Independent risk factors for early recurrence included tumor locations (HR=0.562, p <0.001), pathological T stage (HR=1.829, p <0.001), tumor diameter (HR=1.344, p = 0.039), positive lymph nodes (HR=1.361, p <0.001), and total resected lymph nodes (HR=1.271, p = 044). For the late recurrent patients, there was a much more significant survival advantage for recurrence after concurrent chemoradiotherapy than that after sequential chemoradiotherapy and radiotherapy alone (p = 0.0066). In conclusion, this study defined 21 months of RFS as early recurrence and also identified its risk factors. Concurrent chemoradiotherapy was suggested as preferred post-relapse treatment for late recurrent ESCC patients.
手术后的早期复发会影响癌症患者的预后,但食管鳞状细胞癌(ESCC)患者早期复发的定义及其危险因素仍不明确。本研究回顾性分析了468例手术后复发的ESCC患者的临床资料。采用最小p值法评估无复发生存期(RFS)的最佳临界值以定义早期复发。基于Cox模型确定早期复发的危险因素。区分早期复发的RFS最佳临界值为21个月(p<0.001)。早期复发的独立危险因素包括肿瘤位置(HR=0.562,p<0.001)、病理T分期(HR=1.829,p<0.001)、肿瘤直径(HR=1.344,p=0.039)、阳性淋巴结(HR=1.361,p<0.001)和切除的淋巴结总数(HR=1.271,p=0.044)。对于晚期复发患者,同步放化疗后复发的生存优势比序贯放化疗和单纯放疗后复发更为显著(p=0.0066)。总之,本研究将21个月的RFS定义为早期复发,并确定了其危险因素。建议同步放化疗作为晚期复发ESCC患者复发后的首选治疗方法。